Comparative efficacy of two α1;-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

BJU International

Volumn 93, Issue 6, 2004, Pages 757-762

  De Reijke, T M ^a   Klarskov, P ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alfuzosin; Benign prostatic enlargement; Doxazosin; Efficacy; Lower urinary tract symptoms

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BLADDER NECK STENOSIS; BRAIN ARTERY ANEURYSM; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL DISEASE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYDRONEPHROSIS; HYPESTHESIA; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SYNCOPE; THORAX PAIN; THOUGHT DISORDER; TITRIMETRY; URETER STONE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE FLOW RATE; VISUAL DISORDER; VOMITING;

ADRENERGIC ALPHA-ANTAGONISTS; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 1942446146     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04720.x     Document Type: Article

References (25)

1. Oesterling JE. Benign prostatic hyperplasia. Its natural history, epidemiologic characteristics, and surgical treatment. Arch Fam Med 1992; 1: 257-66
2. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997; 10: 349-66
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
4. Mobley DF, Kaplan S, Ice K, Gaffney M, Dias N. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies. Int J Clin Pract 1997; 51: 282-8
5. Garraway W, Kirby R. Benign prostatic hyperplasia. Effects on quality of life and impact on treatment decisions. Urology 1994; 44: 629-36
6. Eri LM, Tveter KJ. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34
7. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual: A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. Scand J Urol Nephrol Suppl 1994 157: 169-76
8. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 1991; 337: 1457-61
9. Martorana G, Giberti C, Di Silverio F et al. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 1997; 32: 47-53
10. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies, Urology 1996; 48: 406-15
11. Chapple CR, Carter P, Christmas TJ et al. A 3-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6
12. Abrams P. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Eur Urol 1997; 32: 39-46
13. Boyle P. Cultural and linguistic validation of questionnaires for use in international studies: the nine-item BPH-specific quality-of-life scale. Eur Urol 1997; 32 (Suppl. 2): 50-2
14. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42: 36-40
15. Chancellor MB, Rivas DA. American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostate hyperplasia. J Urol 1993; 150: 1706-8
16. Chow W, Hahn D, Sandhu D et al. Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br J Urol 1990; 65: 36-8
17. Chapple CR, Stott M, Abrams PH, Christmas TJ, Milroy EJ. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285-94
18. 1c-adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995; 76: 325-36
19. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study, a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group, Urology 1996; 47: 159-68
20. Hartung R. Do alpha-blockers prevent the occurrence of acute urinary retention? Eur Urol 2001; 39 (Suppl. 6): 13-8
21. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13: 468-74
22. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
23. Lepor H, Kaplan S, Klimberg I et al. Doxazosin for benign prostatic hyperplasia, long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525-30
24. Kirby RS. Doxazosin in benign prostatic hyperplasia, effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 182-6
25. Kaplan SA, Meade-D'Alisera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: 512-7